Vivo Bio Tech Ltd.
Snapshot View

40.00 +0.30 ▲0.8%

18 May 2022, 04:01:00 PM
Volume: 4,225

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website
Market Cap 58.91 Cr.
Enterprise Value(EV) 88.80 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 2.14 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 18.68 Trailing Twelve Months Ending 2021-12
Industry PE 28.96 Trailing Twelve Months Ending 2021-12
Book Value / Share 33.95 Trailing Twelve Months Ending 2021-12
Price to Book Value 1.18 Calculated using Price: 40.00
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 1.49 Cr. 14,876,520 Shares
FaceValue 10
Company Profile

Vivo Bio Tech was incorporated on February 12, 1987 as Golden Growth Fund, Hyderabad-based Vivo Bio Tech (VBTL) is a contract research company engaged in biotechnology and pharma drug discovery activities. The company was converted into a public limited company from Jun. 19, 1992. VBTL provides services ranging from insilico design, wet lab contract research, preclinical research and clinical studies spanning the entire drug discovery value chain.

It is a full service CRO offering drug development & discovery services to pharmaceutical & biotech companies world-wide in accordance with OECD, AAALAC & IND guidelines. The company offers services in the areas of custom research, In-vitro and In-vivo toxicity studies, pharmacological investigations, pharmacokinetics & toxicokinetic studies etc. Our experienced & talented scientists offer advice on defining drug development paths tailored to specific molecules. Tailored and dedicated to our clients, we distinguish your development plan is as superlative as the products you bring to our testing facilities.

The Custom Research Services group at Vivo Bio Tech offers a complete line of protein services, including gene synthesis, cloning, expression and purification of recombinant proteins and monoclonal antibodies. Our scientists will team up with you to develop solution for the most difficult to deal products including purification of untagged & poorly expressed proteins.

In-vitro Services offers solutions for pharmacologic, toxicological & bioanalytical investigations in drug discovery & development. Critical investigations like bacterial reverse mutation assays, chromosomal aberration, and micronucleus are specialty services by our scientists.

Vivo Bio Tech has obtained permission from the Govt. of India for developing Biotech Sector Specific 'Special Economic Zone' at its site (39 acres) in Pregnapur, Gajwel Mandal, Medak District, Andhra Pradesh.The Vivo Bio Tech SEZ is located adjacent to Karimnagar highway road (approx 16 km from ICICI Knowledge Park and SP Biotech Park). The site is approximately 53km from Secunderabad Railway Station and around 90km from the new airport (Shamshabad).

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.76%
1 Week
+4.71%
1 Month
-13.42%
3 Month
6 Month
-35.85%
1 Year
-40.48%
2 Year
+42.86%
5 Year
-58.76%
10 Year
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 5.91 3.52 5.25 9.48 22.17 21.01 10.21 14.85 15.36
Return on Capital Employed (%) 7.83 7.95 4.72 5.96 12.39 15.18 9.58 13.85 18.81
Return on Assets (%) 0.83 0.75 1.14 2.09 5.17 5.64 3.92 7.58 8.02

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 8 9 9 10 13 19 27 33 43 46
Non Curr. Liab. 5 5 4 15 22 15 9 9 15 16
Curr. Liab. 26 26 28 20 17 25 19 21 22 20
Minority Int.
Equity & Liab. 39 40 41 46 51 60 55 62 80 82
Non Curr. Assets 21 21 20 24 32 32 30 35 52 50
Curr. Assets 18 19 22 22 20 28 25 27 27 32
Misc. Exp. not W/O 0 0 0 0 0 0 0 0 0
Total Assets 39 40 41 46 51 60 55 62 80 82

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 14 16 18 29 34 47 56 55 52 52
Other Income 1 1 1 1 0 0 0 0 0 0
Total Income 15 17 19 29 35 47 56 55 52 53
Total Expenditure -12 -14 -15 -25 -27 -36 -46 -43 -34 -34
PBIDT 3 3 4 5 8 11 10 13 18 19
Interest -1 0 -1 0 -1 -2 -3 -3 -4 -4
Depreciation -2 -2 -3 -3 -4 -5 -5 -5 -6 -7
Taxation 0 0 0 0 0 -1 0 0 -3 -4
Exceptional Items
PAT 0 0 0 1 3 3 2 4 6 3
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 0 0 0 1 3 3 2 4 6 3
Adjusted EPS 0 0 0 1 3 3 2 3 4 2

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 5 2 3 2 9 -6 11 -1 9 14
Cash Fr. Inv. -5 25 -1 -2 -7 -12 -5 -4 -10 -23
Cash Fr. Finan. 0 -19 0 -1 0 7 -3 1 2 9
Net Change 0 8 1 -1 1 -11 3 -4 0 0
Cash & Cash Eqvt 2 10 11 11 12 1 4 1 1 1

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 34.70 34.70 34.70 34.70 36.58 39.84 39.84 39.84 39.67
Public 65.30 65.30 65.30 65.30 63.42 60.16 60.16 60.16 60.33
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 16 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year ended 31st March 2022
Mon, 09 May 2022
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Iragavarapu Constructions Pvt Ltd
Mon, 09 May 2022
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Shri Shri Resorts Pvt Ltd

Technical Scans View Details

Wed, 18 May 2022
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
High Decrease 1 Month High Decrease 1 Month
High Decrease 6 Months High Decrease 6 Months
High Decrease 1 Year High Decrease 1 Year
Tue, 17 May 2022
Opening at High Opening at High

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 215,700.21 899.00 +0.8%
Divi's Laboratories Ltd. 115,623.51 4,355.45 +1.2%
Cipla Ltd. 76,889.38 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. 65,126.60 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. 53,689.19 3,734.00 -2.1%
Gland Pharma Ltd. 51,396.43 3,122.95 +0.6%
Piramal Enterprises Ltd. 47,255.41 1,980.00 -0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 33.47 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-12 45.03 4,355.45 +1.2%
Cipla Ltd. Consolidated 2022-03 30.55 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-12 24.64 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 47.37 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-12 43.33 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-12 38.03 1,980.00 -0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.17 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-12 10.67 4,355.45 +1.2%
Cipla Ltd. Consolidated 2022-03 3.69 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-12 3.39 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.70 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-12 7.48 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-12 1.33 1,980.00 -0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 0.10 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,980.00 -0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 14.13 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,980.00 -0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 14.13 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,980.00 -0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,980.00 -0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,980.00 -0.2%